• Diagonal Therapeutics

  Participated · Series B · Jan 2026

  Diagonal Therapeutics engineers first-in-class clustering antibodies that aim to repair faulty cell-signaling pathways driving severe genetic disorders. Its DIAGONAL Product Engine combines proprietary computational and experimental methods to overcome traditional antibody discovery challenges and produce optimized therapeutics. The lead program, DIAG723, targets the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension and is the primary focus of upcoming clinical advancement. Beyond this, the company is building a pipeline of selective clustering antibodies addressing diseases in hematology, hepatology, and nephrology. Funds from the latest raise will be deployed to progress DIAG723 and further pipeline development. Diagonal is led by founder and CEO Alex Lugovskoy and has attracted several blue-chip life-science investors, underscoring strong industry confidence in its platform.

• Valink Therapeutics

  Participated · Series A · Oct 2025

  Valink Therapeutics engineers next-generation oncology therapeutics that combine bispecific antibody technology with antibody-drug conjugates to improve efficacy, safety, and precision. Its proprietary discovery platform and V-gate™ approach expand the design space for bsADCs, enabling fine-tuned target control and an improved therapeutic index compared with current ADC technologies. Beyond bsADCs, the company is building a suite of multispecific or multifunctional ADCs and multivalent agonists to address additional therapeutic needs. Valink is advancing two first-in-class oncology programs for solid tumors, including colorectal cancer, which are now moving toward preclinical development. Proceeds from recent financing will fund this pipeline progression and further platform development. The company operates from its headquarters in Cambridge, Massachusetts, with R&D facilities in the United Kingdom.

• Akribion Therapeutics

  Led · Seed · Feb 2025

  Akribion Therapeutics develops a proprietary G-dase® E nuclease platform that enables RNA-guided, nuclease-based programmable cell depletion by shredding DNA and RNA only when a guide RNA matches an intracellular RNA sequence. The technology is designed to kill only targeted cells while leaving healthy cells unharmed. The company was founded in 2024, spun out of BRAIN Biotech AG, and is based in Zwingenberg, Germany. Akribion is initially focused on precision oncology, specifically HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), and is exploring applications in other oncology indications as well as autoimmune diseases, fibrosis, and infectious diseases. The platform’s guide-RNA-driven adaptability is positioned to speed target switching and accelerate development compared with traditional approaches. A recent seed financing is intended to advance the program toward in vivo proof of concept.

• Alesta Therapeutics

  Participated · Series A · Jan 2025

  Alesta Therapeutics is a Leiden, Netherlands–based biotech focused on developing orally active small-molecule therapies for underserved rare diseases. The company is advancing two lead programs: ALE1, an oral candidate for hypophosphatasia (HPP) that inhibits a novel target to reduce inorganic pyrophosphate (PPi), and ALE2, a GCN2 inhibitor aimed at tRNA‑mutation forms of Charcot‑Marie‑Tooth (CMT). ALE1 was in‑licensed from 1cBio and has shown preclinical PPi reduction across multiple animal models; it is undergoing GLP toxicology studies with clinical studies expected to start in 2025. ALE2 has supporting preclinical data and is being advanced toward clinical development to address chronic neurotoxicity driven by the integrated stress response. The company is led by CEO Ilan Ganot with senior scientific and medical leadership in place and collaborates with academic partners and disease advocacy groups. Alesta announced an oversubscribed €65 million Series A in January 2025 to fund advancement of ALE1 toward clinical proof of concept and to accelerate development of ALE2.

• Arda Therapeutics

  Participated · Series A · Oct 2024

  Arda Therapeutics develops targeted cell depletion therapies that identify and selectively eliminate pathogenic cells via a single-cell-based discovery engine. Its platform detects disease-driving cells and their surface markers to enable targeted biologics that spare healthy tissue. The company positions this approach as applicable across fibrotic conditions (including pulmonary fibrosis), autoimmune and metabolic disorders. Arda aims to progress lead programs toward the clinic and expand its platform to additional disease areas. The company recently appointed Scott Turner, Ph.D., as chief scientific officer to advance fibrosis and biomarker strategies. Arda announced a $43 million Series A to fund clinical progression and platform expansion.

No current team members are available.